Biodegradable stents as a platform to drug loading.

Area of Science:

• Biomaterials Science
• Cardiovascular Medicine
• Pharmacology

Background:

• Coronary restenosis due to in-stent neointimal hyperplasia remains a significant challenge despite advancements in coronary stenting.
• Conventional oral pharmacological treatments have proven ineffective in reducing restenosis, likely due to inadequate local drug concentrations.
• Drug-eluting stents (DES) have emerged as a strategy for localized drug delivery to mitigate this issue.

Purpose of the Study:

• To develop and evaluate a novel drug-eluting polymer stent for the local delivery of tranilast.
• To investigate the potential advantages of drug-mixed polymer stents over polymer-coated metallic stents for restenosis prevention.

Main Methods:

• Development of a drug-eluting stent using poly-l-lactic acid (PLLA) polymer mixed with tranilast.
• Tranilast, an anti-allergic agent, was incorporated to inhibit vascular smooth muscle cell migration and proliferation.
• Comparison of drug-loading capacity between drug-mixed polymer stents and drug-coated metallic stents.

Main Results:

• The developed polymer stent is designed for local administration of tranilast, targeting neointimal hyperplasia.
• Drug-mixed polymer stents demonstrate a higher drug-loading capacity compared to drug-coated metallic stents.
• Polymer stents offer potential advantages in biodegradation and drug elution compared to coated metallic stents.

Conclusions:

• The novel tranilast-eluting poly-l-lactic acid stent presents a potential new therapeutic strategy for preventing in-stent restenosis.
• Drug-mixed polymer stents may offer superior drug delivery capabilities for managing neointimal hyperplasia.
• Further clinical studies are essential to establish the safety and efficacy of these drug-eluting polymer stents in patients.